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Abstract
Multidrug-resistant (MDR) Gram-negative bacteria have emerged as a serious threat to human and animal health.
Bdellovibrio spp. and Micavibrio spp. are Gram-negative bacteria that prey on other Gram-negative bacteria. In this study,
the ability of Bdellovibrio bacteriovorus and Micavibrio aeruginosavorus to prey on MDR Gram-negative clinical strains was
examined. Although the potential use of predatory bacteria to attack MDR pathogens has been suggested, the data
supporting these claims is lacking. By conducting predation experiments we have established that predatory bacteria have
the capacity to attack clinical strains of a variety of ß-lactamase-producing, MDR Gram-negative bacteria. Our observations
indicate that predatory bacteria maintained their ability to prey on MDR bacteria regardless of their antimicrobial resistance,
hence, might be used as therapeutic agents where other antimicrobial drugs fail.
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Introduction
Since antimicrobial drugs were first discovered they have saved
countless lives. However, pathogenic multidrug-resistant (MDR)
bacteria have emerged as a serious threat to human health. Of
particular concern are MDR Gram-negative bacteria producing
highly potent ß-lactamases such as the extended-spectrum ß-
lactamase and KPC-type ß-lactamase [1]. It is estimated that in
the United States alone nearly 2 million patients develop hospital-
acquired infection yearly [2], many of which are caused by these
MDR pathogens. The magnitude of the problem has highlighted
the need to develop new ways to control infection.
An alternative approach to combat antimicrobial-resistant
bacterial infections is the use of predatory bacteria to eliminate
MDR pathogens. Bdellovibrio spp. and Micavibrio spp. are Gram-
negative bacteria which belong to the delta and alpha subgroup of
proteobacteria respectively [3,4]. The Bdellovibrio life cycle involves
attack phase cell that seek, attach to, and invade a Gram-negative
bacterial host, and a growth phase cell that develops within the
host [5–7]. The Micavibrio life cycle also exhibits an attack phase
cell that allows it to find its Gram-negative bacterial host and to
attach to the prey’s surface, followed by extracellular growth of the
predator [8–10]. We have previously demonstrated that both
Bdellovibrio and Micavibrio have the potential to prey on a wide
range of human pathogens grown both planktonically and as
a biofilm [11–13]. However, the majority of the studies utilized
culture collection reference strains or clinical strains for which the
antibiotic susceptibility data were lacking [11,13]. Therefore, the
ability of predator bacteria to attack contemporary clinical strains
of MDR bacteria has remained unclear. To address this question,
we examined the capacity of the two predatory bacteria to prey on
MDR Gram-negative clinical strains producing clinically relevant
ß-lactamases and representing various opportunistic nosocomial
pathogens.
Materials and Methods
A total of 14 MDR clinical strains isolated between 2005 and
2011 were tested, including Acinetobacter baumannii [2], Escherichia
coli [5], Klebsiella pneumoniae [5], and Pseudomonas spp. [2]. They
were selected to include species which are commonly encountered
clinically, and to represent a variety of potent ß-lactamases,
including extended-spectrum ß-lactamase (ESBL), KPC-type
carbapenemase, AmpC-type ß-lactamase, and metallo-ß-lacta-
mase. Antimicrobial susceptibility was tested using the disk
diffusion method and interpreted according to the breakpoints
endorsed by the Clinical and Laboratory Standards Institute
(CLSI) (Table 1) [14]. The ß-lactamases produced were charac-
terized previously [15,16] or otherwise determined by PCR and
sequencing [17]. Three predatory bacteria were used in this study:
Bdellovibrio bacteriovorus 109J (ATCC 43826), B. bacteriovorus HD100
and Micavibrio aeruginosavorus strain ARL-13 [5,10]. The predators
were grown and maintained as described before [11]. Predator
stock-lysates were made by co-culturing host cells with the
predators in diluted nutrient broth (DNB) and allowing the co-
culture to incubate at 30uC on a rotary shaker until the culture
became clear. To culture the predators, co-cultures were prepared
by adding 2 ml of washed host cells (,16109 CFU/ml) to 2 ml of
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predatory bacteria stock-lysate in 20 ml of DNB. The co-cultures
were incubated for 24 hrs until the predator reached a final
concentration of ,16108 PFU/ml. Thereafter, the lysates were
filtered through a 0.45-mm Millex pore-size filter (Millipore,
Billerica, MA) in order to remove remaining host cells (predator
filtered lysate). As a control, filtered sterilized lysate was prepared
by passing the lysates through three 0.22 mm pore-size filters
[12,13]. Predation experiments were conducted as described
previously [11]. In brief, 5 ml of DNB co-cultures were made by
adding to 0.5 ml of washed host cells to 0.5 ml of predator filtered
lysate or predator-free control. The cultures were placed at 30uC
on a rotary shaker for 48 hrs.
Results and Discussion
The ability of each predator to attack the host was measured by
the reduction in host cell viability, determined by dilution plating
and CFU enumeration, and compared to the initial host
concentration and predator-free control. Cell viability was
measured following 24 and 48 hrs of incubation. Each co-culture
Table 1. Host pathogens used in the study and their antibiotic susceptibility.
Bacteria and strain Source ß-lactamase gene Antibiotic susceptibility
Acinetobacter baumannii
AB276 Sputum OXA-23 Ceftazidime (R); Cefotaxime (R); Cefepime (S); Imipenem (I);
Meropenem (R); Gentamicin (R); Amikacin (R); Ciprofloxacin (R);
Tetracycline (R); Trimethoprim-sulfamethoxazole (R)
AB285 Donor bronchus OXA-40 Ceftazidime (R); Cefotaxime (R); Cefepime (R); Imipenem (R);
Meropenem (R); Gentamicin (R); Amikacin (R); Ciprofloxacin (R);
Tetracycline (R); Trimethoprim-sulfamethoxazole (R)
Escherichia coli
YD429 Urine CTX-M-15 Ceftazidime (I); Cefotaxime (R); Cefepime (S); Imipenem (S);
Meropenem (S); Gentamicin (R); Amikacin (S); Ciprofloxacin (R);
Tetracycline (R); Trimethoprim-sulfamethoxazole (R)
YD438 Blood SHV-7 Ceftazidime (S); Cefotaxime (S); Cefepime (S); Imipenem (S);
Meropenem (S); Gentamicin (S); Amikacin (S); Ciprofloxacin (R);
Tetracycline (R); Trimethoprim-sulfamethoxazole (S)
YD446 Urine CTX-M-14 Ceftazidime (S); Cefotaxime (R); Cefepime (S); Imipenem (S);
Meropenem (S); Gentamicin (S); Amikacin (S); Ciprofloxacin (R);
Tetracycline (R); Trimethoprim-sulfamethoxazole (R)
YDC354 Urine KPC-2 Ceftazidime (R); Cefotaxime (R); Cefepime (S); Imipenem (R);
Meropenem (R); Gentamicin (S); Amikacin (S); Ciprofloxacin (R);
Tetracycline (R); Trimethoprim-sulfamethoxazole (R)
AZ1285 Blood CMY-33 Ceftazidime (R); Cefotaxime (R); Cefepime (R); Imipenem (S);
Meropenem (S); Gentamicin (S); Amikacin (S); Ciprofloxacin (R);
Tetracycline (R); Trimethoprim-sulfamethoxazole (S)
Klebsiella pneumoniae
YD466 Wound KPC-2 Ceftazidime (R); Cefotaxime (R); Cefepime (R); Imipenem (R);
Meropenem (R); Gentamicin (S); Amikacin (R); Ciprofloxacin (R);
Tetracycline (S); Trimethoprim-sulfamethoxazole (R)
AZ1032 Blood SHV-7 Ceftazidime (R); Cefotaxime (R); Cefepime (S); Imipenem (S);
Meropenem (S); Gentamicin (R); Amikacin (S); Ciprofloxacin (S);
Tetracycline (S); Trimethoprim-sulfamethoxazole (R)
AZ1093 Blood SHV-5 Ceftazidime (R); Cefotaxime (R); Cefepime (I); Imipenem (S);
Meropenem (S); Gentamicin (R); Amikacin (R); Ciprofloxacin (S);
Tetracycline (S); Trimethoprim-sulfamethoxazole (R)
AZ1136 Blood CTX-M-2 Ceftazidime (R); Cefotaxime (R); Cefepime (R); Imipenem (S);
Meropenem (I); Gentamicin (R); Amikacin (R); Ciprofloxacin (R);
Tetracycline (S); Trimethoprim-sulfamethoxazole (R)
AZ1169 Blood SHV-12 Ceftazidime (R); Cefotaxime (R); Cefepime (S); Imipenem (S);
Meropenem (S); Gentamicin (S); Amikacin (S); Ciprofloxacin (R);
Tetracycline (S); Trimethoprim-sulfamethoxazole (R)
Pseudomonas aeruginosa
GB771 Sputum PME-1 Ceftazidime (R); Cefotaxime (R)1; Cefepime (R); Imipenem (R);
Meropenem (R); Gentamicin (R); Amikacin (S); Ciprofloxacin (R);
Tetracycline (R)1; Trimethoprim-sulfamethoxazole (R)1
Pseudomonas putida
YA241 Sputum VIM-1 Ceftazidime (R); Cefotaxime (R)1; Cefepime (R); Imipenem (R);
Meropenem (R); Gentamicin (R); Amikacin (S); Ciprofloxacin (R);
Tetracycline (I)1; Trimethoprim-sulfamethoxazole (R)1
(R) Resistant; (I) intermediate; (S) susceptible.
1Breakpoints are not defined for cefotaxime, tetracycline and trimethoprim-sulfamethoxazole by the CLSI; interpretation based on the breakpoints for A. baumannii.
doi:10.1371/journal.pone.0063397.t001
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was performed in triplicate. The ability of the predators to attack
each of the MDR pathogens is shown in Table 2. B. bacteriovorus
HD100 was able to prey on all examined host bacteria with
a greater than 2, 3 and 4 log10 reduction measured for 93%, 78%
and 35% of the attacked strains, respectively. B. bacteriovorus 109J
was able to prey on 13 of the 14 host bacteria (93%) with a greater
than 2, 3 and 4 log10 reduction measured for 85%, 64% and 28%
of the predation positive strains, respectively. Five out of the 7
(71%) examined host bacteria were reduced by M. aeruginosavorus
ARL-13, with 80% and 40% of the predator-susceptible strains
showing a 2 and 3 log10 reduction, respectively. In this study
Micavibrio was examined only on P. aeruginosa and K. pneumoniae as
previous study suggested that M. aeruginosavorus ARL-13 is most
capable of preying on these pathogens [11,13]. The predators
maintained their ability to prey on the host cells despite the MDR
status. Furthermore, no clear patterns emerged when comparing
the antibiotic susceptibility of the host cells to predation. The
different host specificity observed for each predator, as well as the
differential capacity of each predator strain to prey on certain
stains within the same species, is well documented for both
Bdellovibrio and Micavibrio [6,9,11,13,18–20]. However, as the
mechanisms that govern host specificity are not fully understood, it
is difficult to speculate on the reason way some host strains are
consumed by the predators whereas others are not.
Conclusions
With the increased occurrence of MDR pathogens, many of
which can no longer be treated adequately by conventional
antimicrobial agents, becoming a major clinical concern, the
concept of using predatory bacteria as live antimicrobials is
gaining momentum [21–23]. Although the putative ability of
predatory bacteria to attack MDR pathogens was hypothesized, it
was never clearly demonstrated. Our data confirms that predatory
bacteria maintained their ability to prey on MDR bacteria
regardless of their antimicrobial resistance. This study further
highlight the potential application of predatory bacteria as
a biological control agent with the capability to prey on MDR
Gram-negative pathogens which are currently found in clinical
settings.
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Table 2. Change in host viability following predation.
Bacteria and
strain
Time0
(CFU/ml)
Control
(Log10 change)
B. bacteriovorus 109J
(Log10 change)
B. bacteriovorus HD100
(Log10 change)
M. aeruginosavorus
ARL-13
(Log10 change)
Acinetobater baumannii
AB276 3.386108 +0.4760.21 23.9260.27 23.7960.07 na
AB285 2.506108 +0.1260.28 23.5660.06 22.7560.11 na
Escherichia coli
YD429 3.136108 +0.0360.02 21.760.20 23.6860.11 na
YD438 1.386108 +0.0960.51 23.5560.20 23.8960.84 na
YD446 4.506108 +0.0760.03 22.9660.18 23.260.3* na
YDC354 4.256108 +0.0160.11 20.160.12*Y 23.7260.07 na
AZ1285 6.006108 +0.8061.13 23.6160.07 23.860.84 na
Klebsiella pneumoniae
YD466 3.636108 +0.2460.18 23.9960.36 23.7360.20 22.9160.19
AZ1032 4.386108 +0.0760.05 22.7560.10 24.0460.56 20.0560.07Y
AZ1093 4.306108 +0.2860.23 22.4260.07 24.0960.39 20.7060.11Y
AZ1136 4.636108 +0.0860.03 23.5460.36 22.8360.09 23.0160.19
AZ1169 4.616108 20.4360.20 24.5160.55 21.7960.15 22.8560.05*
Pseudomonas aeruginosa
GB771 2.536108 +0.7160.26 23.9660.32* 23.0760.68 22.6460.29
Pseudomonas putida
YA241 6.256106 +0.9460.22 22.460.14 23.9060.35 21.4160.35
Co-cultures were prepared by adding host cells to harvested predator cells (,16107 PFU) or predator free control. Values represent the maximum log10 change
measured following 24 or 48 (*) hrs of incubation (compared to t0). Each experiments was conducted in triplicates with value representing the mean and standard error.
n.a- not applicable.
Y= experiment was conducted twice yielding similar result.
Time 0- initial host concentration (CFU/ml).
+= Increase in host numbers.
2= Decrease in host numbers.
doi:10.1371/journal.pone.0063397.t002
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